Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBYCLOR vs BENICAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Treatment of hypertension to lower blood pressure; lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Treatment of hypertension in adults and children ≥6 years,Off-label: Diabetic nephropathy, heart failure
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan; azilsartan is metabolized primarily by CYP2C9. Chlorthalidone is minimally metabolized, with most of the dose excreted unchanged in urine.
Prodrug olmesartan medoxomil is rapidly hydrolyzed to active olmesartan by esterases in gastrointestinal tract. Olmesartan is not metabolized by CYP450 enzymes and is excreted unchanged in bile and urine.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Azilsartan: >99% bound to serum albumin; chlorthalidone: approximately 75% bound to albumin and lipoproteins
Highly protein-bound (approximately 99%) to serum albumin.
Azilsartan: approximately 16 L (0.2 L/kg) indicating limited extravascular distribution; chlorthalidone: approximately 3-4 L/kg (extensive tissue binding, particularly to erythrocytes)
Volume of distribution is approximately 17 L (0.2–0.3 L/kg), indicating limited extravascular distribution.
Azilsartan medoxomil: absolute bioavailability approximately 60% (oral); chlorthalidone: approximately 65% (oral)
Oral bioavailability is about 26–29% (absolute).
e GFR <30 m L/min/1.73m2: not recommended. No adjustment required for e GFR ≥30 m L/min/1.73m2.
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initial dose 20 mg once daily; maximum 40 mg/day.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): contraindicated. Child-Pugh Class C (severe): contraindicated.
No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe impairment (Child-Pugh C).
Not established; safety and efficacy in pediatric patients have not been studied.
Safety and efficacy not established for pediatric patients <18 years.
Initiate with the lowest available dose (40 mg/12.5 mg) and titrate cautiously due to increased risk of hypotension and electrolyte disturbances.
Initial 20 mg once daily; caution due to potential for reduced renal function. Monitor BP and electrolytes.
None
No FDA black box warning.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause oligohydramnios, fetal renal dysfunction, and neonatal hypotension, hyperkalemia, and skull hypoplasia. Discontinue Edarbyclor as soon as possible when pregnancy is detected.,Hypotension: Correct volume- or salt-depleted patients prior to initiation; monitor for symptomatic hypotension.,Electrolyte disturbances: Chlorthalidone may cause hypokalemia, hyponatremia, and hypomagnesemia. Monitor electrolytes periodically.,Renal function deterioration: Monitor renal function in patients with renal artery stenosis, severe heart failure, or volume depletion.,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant use of potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium.,Acute angle-closure glaucoma: Chlorthalidone, as a sulfonamide derivative, can cause idiosyncratic reaction leading to acute transient myopia and acute angle-closure glaucoma.,Exacerbation of systemic lupus erythematosus: Chlorthalidone may exacerbate or activate SLE.,Metabolic: Chlorthalidone may increase serum glucose, uric acid (precipitating gout), and decrease urinary calcium excretion.,Sulfonamide allergy: Chlorthalidone is a sulfonamide derivative; caution in patients with sulfonamide allergy.
May cause fetal harm if used during pregnancy,Avoid use in patients with severe renal impairment (Cr Cl <20 m L/min),Sprue-like enteropathy (severe chronic diarrhea with weight loss),Hypotension in volume-depleted patients,Hyperkalemia,Renal function deterioration in patients with renal artery stenosis
Anuria,Hypersensitivity to azilsartan medoxomil, chlorthalidone, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes mellitus
Concomitant use with aliskiren in patients with diabetes mellitus,History of hypersensitivity to any component of the product
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, salt substitutes) in excess due to risk of hyperkalemia. Avoid excessive salt intake. Grapefruit juice may alter drug metabolism; limit or avoid consumption. Alcohol may potentiate hypotensive effects.
No significant food interactions; may be taken with or without food. However, avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) if renal impairment is present or if taking potassium supplements.
First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the second and third trimesters. There is no known risk of major malformations with first trimester exposure, but data are limited. Second and third trimesters: Use is contraindicated due to fetal renal dysfunction, oligohydramnios, pulmonary hypoplasia, limb contractures, and neonatal anuria, hypotension, and death. Azilsartan medoxomil (ARB) and chlorthalidone (thiazide diuretic) both affect RAS and fetal hemodynamics.
Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data are limited. Use in the second and third trimesters is known to cause fetal renal dysfunction, oligohydramnios, skull ossification deficits, and neonatal hypotension, hyperkalemia, and renal failure.
No data on azilsartan medoxomil or chlorthalidone presence in human milk, effects on the breastfed infant, or milk production. Chlorthalidone is present in breast milk at low levels; M/P ratio unknown. Due to potential for adverse effects in the nursing infant (e.g., hypotension, renal impairment), alternative agents are recommended.
Minimal excretion into breast milk; M/P ratio is unknown. The American Academy of Pediatrics considers use compatible with breastfeeding, but caution is advised in preterm infants or those with renal impairment.
EDARBYCLOR is not recommended in pregnancy, especially during second and third trimesters; if exposure occurs, discontinue as soon as possible. No specific dose adjustment studied; however, pregnancy can increase volume of distribution and clearance of some antihypertensives, but no data for this combination. Use is contraindicated after first trimester.
No dose adjustment typically required in pregnancy, but pharmacokinetic changes (increased volume of distribution, altered renal clearance) may necessitate careful blood pressure monitoring and dose titration. Avoid use during second and third trimesters if possible.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil (an ARB) and chlorthalidone (a thiazide-like diuretic). Monitor renal function and electrolytes regularly due to risk of hypotension, hyperkalemia, and hyponatremia. Avoid use in patients with anuria or severe renal impairment (e GFR <30 m L/min). Chlorthalidone may exacerbate gout and hyperuricemia. Use caution in patients with hepatic impairment or diabetes.
BENICAR (olmesartan) is an angiotensin II receptor blocker (ARB) used primarily for hypertension. It demonstrates a dose-dependent antihypertensive effect with a once-daily dosing regimen. Monitor renal function and serum potassium, especially in patients with renal impairment or those on potassium-sparing diuretics. Avoid use in pregnancy (category D).
Take this medication exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by your doctor.,Drink plenty of fluids unless otherwise directed by your healthcare provider.,Report symptoms of low blood pressure (dizziness, fainting), electrolyte imbalance (muscle cramps, weakness), or kidney problems (decreased urination).,This drug may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Tell your doctor if you are pregnant or planning to become pregnant; this drug can cause fetal harm.,Limit alcohol intake as it may worsen side effects.,Do not stop taking this medication abruptly without consulting your doctor.
Take exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to see full blood pressure lowering effect.,Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium (muscle weakness, slow heartbeat) or low blood pressure (dizziness, fainting).,Stay hydrated but avoid excessive dehydration (e.g., from diarrhea or vomiting).,Do not abruptly stop this medication without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBYCLOR vs BENICAR, answered by our medical review team.
EDARBYCLOR is a Angiotensin II Receptor Blocker/Thiazide Diuretic Combination that works by EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.. BENICAR is a Angiotensin II Receptor Blocker that works by Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBYCLOR and BENICAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBYCLOR is: One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.. The standard adult dose of BENICAR is: Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBYCLOR and BENICAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBYCLOR is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the secon. BENICAR is classified as Category C. Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.